Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy
NCT00087503
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class
Conditions
Stomach Neoplasms
Interventions
DRUG:
Edotecarin
Sponsor
Pfizer